Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Go back to Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors| (NASDAQ: NVCT) | Delayed: 24.49 +0.12 (0.49%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.37 | 52 Week High | $ | |||
| Open | $24.00 | 52 Week Low | $ | |||
| Day High | $25.19 | P/E | N/A | |||
| Day Low | $23.96 | EPS | $ | |||
| Volume | 117,166 | |||||
